Join to View Full Profile
200 TECHNOLOGY SQUARECambridge, MA 02139
Phone+1 617-528-8375
Dr. Do is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board certified oncologist specializing in early drug development. I completed by training at the National Cancer Institute, National Institutes of Health.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2010 - 2014- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2009 - 2014
George Washington UniversityResidency, Internal Medicine, 2006 - 2009- George Washington University School of Medicine and Health SciencesClass of 2006
Certifications & Licensure
VA State Medical License 2009 - 2026
MA State Medical License 2014 - 2025
NH State Medical License 2024 - 2024
DC State Medical License 2006 - 2009
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer Start of enrollment: 2020 Sep 01
Publications & Presentations
PubMed
- Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer o...Ana C Garrido-Castro, Noah Graham, Lestat R Ali, Christina Herold, Jennifer Desrosiers
Journal for Immunotherapy of Cancer. 2025-02-25 - A Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors.Gregory M Cote, Bose S Kochupurakkal, Khanh Do, Andrea Bullock, Michael L Cheng
Clinical Cancer Research. 2025-01-06 - 5 citationsPhase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.Ryan B Corcoran, Khanh T Do, Jeong E Kim, James M Cleary, Aparna R Parikh
Clinical Cancer Research. 2024-05-01
Lectures
- Phase 1 Safety, Pharmacokinetic, and Pharmacodynamic Study of Fadraciclib (CYC065), a cyclin-dependent kinase inhibitor, in Patients with Advanced Solid Tumors32nd EORTC/AACR/NCI Virtual Symposium 24-25 October 2020 - 10/25/2020
- Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced...ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
- Phase I combination study of the CHK1 inhibitor prexasertib (LY2606368) and olaparib in patients with high-grade serous ovarian cancer and other advanced solid tumorsAACR Annual Meeting - Atlanta, GA 2019 - 4/2/2019
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
